share_log

Recursion Pharmaceuticals | DEFA14A: Others

Recursion Pharmaceuticals | DEFA14A: Others

Recursion Pharmaceuticals | DEFA14A：其他
美股SEC公告 ·  09/19 16:30
Moomoo AI 已提取核心訊息
Recursion Pharmaceuticals, Inc., a biotech firm specializing in AI-driven drug discovery, has announced a proposed transaction with Exscientia plc, a company known for its algorithmic approach to medicinal chemistry. The merger aims to create a 'full-stack' small-molecule discovery engine, leveraging both companies' strengths in biology and chemistry to accelerate drug development. Recursion's Chief R&D Officer, Najat Khan, who joined the company after a tenure at Johnson & Johnson, highlighted the merger's potential to enhance Recursion's drug development infrastructure and expand its chemistry capabilities. The transaction, which has been in the works for over a month, is expected to diversify Recursion's pipeline with ten programs across oncology, immunology, and neuroscience. The preliminary joint proxy statement was filed with the SEC on September 17, 2024, and the definitive joint proxy statement will be provided to stockholders and shareholders detailing the transaction's terms and benefits. The proposed merger is anticipated to close by early 2025, subject to stockholder approval, regulatory clearances, and other customary closing conditions.
Recursion Pharmaceuticals, Inc., a biotech firm specializing in AI-driven drug discovery, has announced a proposed transaction with Exscientia plc, a company known for its algorithmic approach to medicinal chemistry. The merger aims to create a 'full-stack' small-molecule discovery engine, leveraging both companies' strengths in biology and chemistry to accelerate drug development. Recursion's Chief R&D Officer, Najat Khan, who joined the company after a tenure at Johnson & Johnson, highlighted the merger's potential to enhance Recursion's drug development infrastructure and expand its chemistry capabilities. The transaction, which has been in the works for over a month, is expected to diversify Recursion's pipeline with ten programs across oncology, immunology, and neuroscience. The preliminary joint proxy statement was filed with the SEC on September 17, 2024, and the definitive joint proxy statement will be provided to stockholders and shareholders detailing the transaction's terms and benefits. The proposed merger is anticipated to close by early 2025, subject to stockholder approval, regulatory clearances, and other customary closing conditions.
Recursion Pharmaceuticals, Inc.，一家專注於人工智能驅動藥物發現的生物科技公司，宣佈與以算法方法著稱於醫藥化學的Exscientia plc擬議的交易。合併旨在打造一個「全套」小分子發現引擎，利用兩家公司在生物學和化學領域的實力加快藥物開發。Recursion的研發總監Najat Khan，在結束與強生公司的任職後加入Recursion，強調了此次合併對提升Recursion的藥物開發製造行業和擴展其化學能力的潛力。此項交易已進行了一個多月，預計將通過將Recursion的管道多樣化，涵蓋腫瘤學、免疫學和神經科學領域的十個項目。初步聯合代理報告已於2024年9月17日向美國證券交易委員會提交，最終的聯合代理報告將向股東提供詳細說明交易條款和好處。擬議的合併預計將於2025年初完成，需要股東批准、獲得監管許可以及其他慣例的關閉條件。
Recursion Pharmaceuticals, Inc.，一家專注於人工智能驅動藥物發現的生物科技公司，宣佈與以算法方法著稱於醫藥化學的Exscientia plc擬議的交易。合併旨在打造一個「全套」小分子發現引擎，利用兩家公司在生物學和化學領域的實力加快藥物開發。Recursion的研發總監Najat Khan，在結束與強生公司的任職後加入Recursion，強調了此次合併對提升Recursion的藥物開發製造行業和擴展其化學能力的潛力。此項交易已進行了一個多月，預計將通過將Recursion的管道多樣化，涵蓋腫瘤學、免疫學和神經科學領域的十個項目。初步聯合代理報告已於2024年9月17日向美國證券交易委員會提交，最終的聯合代理報告將向股東提供詳細說明交易條款和好處。擬議的合併預計將於2025年初完成，需要股東批准、獲得監管許可以及其他慣例的關閉條件。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息